-
-
-
-
-
-
-
Corbus Pharmaceuticals (CRBP) PT Lowered to $52 at Oppenheimer
-
-
-
-
-
-
-
Corbus Pharmaceuticals completes enrollment in obesity drug trial
-
-
-
-
-
-
-
Corbus Pharmaceuticals (CRBP) PT Raised to $51 at Piper Sandler
-
-
-
-
-
-
-
Corbus Pharma (CRBP) Misses Q2 EPS by 144c
-
-
-
-
-
-
-
Corbus Pharmaceuticals (CRBP) PT Lowered to $50 at H.C. Wainwright
-
-
-
-
-
-
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)
-
456,295 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

